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Abstract
Background: Human immunodeficiency virus type 1 (HIV-1) productively infects only humans and
chimpanzees but not cynomolgus or rhesus monkeys while simian immunodeficiency virus isolated
from macaque (SIVmac) readily establishes infection in those monkeys. Several HIV-1 and SIVmac
chimeric viruses have been constructed in order to develop an animal model for HIV-1 infection.
Construction of an HIV-1 derivative which contains sequences of a SIVmac239 loop between -
helices 4 and 5 (L4/5) of capsid protein (CA) and the entire SIVmac239 vif gene was previously
reported. Although this chimeric virus could grow in cynomolgus monkey cells, it did so much
more slowly than did SIVmac. It was also reported that intrinsic TRIM5 restricts the post-entry
step of HIV-1 replication in rhesus and cynomolgus monkey cells, and we previously demonstrated
that a single amino acid in a loop between -helices 6 and 7 (L6/7) of HIV type 2 (HIV-2) CA
determines the susceptibility of HIV-2 to cynomolgus monkey TRIM5.
Results: In the study presented here, we replaced L6/7 of HIV-1 CA in addition to L4/5 and vif
with the corresponding segments of SIVmac. The resultant HIV-1 derivatives showed enhanced
replication capability in established T cell lines as well as in CD8+ cell-depleted primary peripheral
blood mononuclear cells from cynomolgus monkey. Compared with the wild type HIV-1 particles,
the viral particles produced from a chimeric HIV-1 genome with those two SIVmac loops were less
able to saturate the intrinsic restriction in rhesus monkey cells.
Conclusion: We have succeeded in making the replication of simian-tropic HIV-1 in cynomolgus
monkey cells more efficient by introducing into HIV-1 the L6/7 CA loop from SIVmac. It would be
of interest to determine whether HIV-1 derivatives with SIVmac CA L4/5 and L6/7 can establish
infection of cynomolgus monkeys in vivo.
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Background
Human immunodeficiency virus type 1 (HIV-1) produc-
tively infects only humans and chimpanzees but not Old
World monkeys (OWM) such as cynomolgus (CM) and
rhesus (Rh) monkeys [1]. Unlike the simian immunodefi-
ciency virus isolated from macaques (SIVmac), HIV-1 rep-
lication is blocked early after viral entry, before the
establishment of a provirus in OWM cells [1-3]. This
restricted host range of HIV-1 has greatly hampered its use
in animal experiments and has caused difficulties for
developing prophylactic vaccines and understanding HIV-
1 pathogenesis. In order to establish a monkey model of
HIV-1/AIDS, various chimeric viral genomes between SIV-
mac and HIV-1 (SHIV) have been constructed and tested
for their replicative capabilities in simian cells. The first
SHIV was generated on a genetic background of SIVmac
with HIV-1 tat, rev, vpu, and env genes [4]. Although such
a SHIV is useful for the analysis of humoral immune
responses against the Env protein [5-7], SHIVs containing
other HIV-1 structural proteins, especially the Gag-Pol
protein, have become highly desirable, since cellular
immune response against Gag is generally believed to be
important for disease control [8-10].
In recent years, several host factors involved in HIV-1
restriction in OWM cells have been identified. ApoB
mRNA editing catalytic subunit (APOBEC) 3 G modifies
the minus strand viral DNA during reverse transcription,
resulting in an impairment of viral replication [11-13].
This activity could be counteracted with the viral protein
Vif [14-17]. Although HIV-1 Vif can potently suppress
human APOBEC3G, it is not effective against Rh
APOBEC3G, which explains at least partly why HIV-1 rep-
lication is restricted in monkey cells. It is well known that
Cyclophilin A (CypA) binds directly to the exposed loop
between -helices 4 and 5 (L4/5) of HIV-1 capsid protein
(CA), but not to the SIVmac CA. Several studies have
found that CypA augments HIV-1 infection in human
cells but inhibits its replication in OWM cells [18-20]. A
construction of a SHIV with a minimal segment of SIVmac
was reported recently by Kamada et al. [21]. This SHIV
was designed to evade the restrictions mediated by
APOBEC3G and CypA in OWM cells and contains the 7-
aa segment corresponding to the L4/5 of CA and the entire
vif of SIVmac. The SHIV was found to be able to replicate
in primary CD4+ T cells from pig-tailed monkey as well as
in the CM HSC-F T cell line. Both in HSC-F and in primary
CD4+ T cells, this chimeric virus grew to lower titers than
did SIVmac [21]; and when inoculated into pig-tailed
monkeys, this SHIV did not cause CD4+ T cell depletion
or any clinical symptoms in the inoculated animals [22].
Another SHIV, stHIV-1 (a virus carrying 202 amino acid
residues of SIVmac CA and vif generated by Hatziioannou
et al.) could replicate efficiently in Rh cells [23]. However,
long-term passaging in Rh cells was necessary to generate
an efficiently replicating stHIV-1, and this adapted virus
has not yet been fully characterized; so it may be that fur-
ther modifications of the viral genome are necessary for
optimal replication of HIV-1 genomes in OWM cells.
TRIM5, a member of the tripartite motif (TRIM) family
proteins, was identified in 2004 as another intrinsic
restriction factor of HIV-1 in OWM cells [24]. Rh and CM
TRIM5 were found to restrict HIV-1 but not SIVmac
[25,26]. TRIM5 recognizes the multimerized CA of an
incoming virus by its -isoform specific SPRY domain
[27-29] and is believed to be involved in innate immunity
to control retroviral infection [30]. Previously, Ylinen et
al. mapped one of the determinants of TRIM5 sensitivity
in L4/5 of HIV type 2 (HIV-2) CA [31]. In addition, we
identified a single amino acid of the surface-exposed loop
between -helices 6 and 7 (L6/7) of HIV-2 CA as a deter-
minant of the susceptibility of HIV-2 to CM TRIM5 [32].
We hypothesized that the L6/7 of HIV-1 CA also deter-
mines susceptibility to CM TRIM5. Here, we investigated
whether an additional replacement of L6/7 of HIV-1 CA
with that of SIVmac would enhance the replication capa-
bility of a SHIV genome in established T cell line HSC-F
and in CD8+ cell depleted peripheral blood mononuclear
cells (PBMCs) from CMs.
Materials and methods
DNA constructions
The HIV-1 derivatives were constructed on a background
of infectious molecular clone NL4-3 [33]. NL-ScaVR, a
virus containing SIVmac239 L4/5 and the entire vif gene,
was constructed according to the procedure described by
Kamada et al. [21]. A single amino acid His (H) at the
120th position of NL-ScaVR CA was replaced with Gln
(Q) by means of site-directed mutagenesis with the PCR-
mediated overlap primer extension method [34], and the
resultant construct was designated NL-ScaVRA1. The L6/7
of CA (HNPPIP) of NL-SVR, NL-ScaVR, or NL-DT5R was
also replaced with the corresponding segments of
SIVmac239 CA (RQQNPIP) by means of site-directed
mutagenesis, and the resultant constructs were designated
NL-SVR6/7S, NL-ScaVR6/7S, or NL-DT5R6/7S, respec-
tively. The BssHII-ApaI fragment of NL-ScaVR, NL-SVR6/
7S, or NL-ScaVR6/7S, which corresponds to matrix (MA)
and CA, was transferred to env deleted NL4-3 (NL-Nhe) to
generate the env (-) version of each of the constructs.
Cells and Virus propagation
The 293 T (human kidney), LLC-MK2 (Rh kidney), and
TK-ts13 (hamster kidney) adherent cell lines were cul-
tured in Dulbecco's modified Eagle medium supple-
mented with 10% heat-inactivated FBS. The CD4+
CXCR4+ CM T cell line HSC-F [35] was maintained in
RPMI 1640 medium containing 10% FBS. Virus stocks
were prepared by transfection of 293 T cells with HIV-1Retrovirology 2009, 6:70 http://www.retrovirology.com/content/6/1/70
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NL4-3 derivatives using the calcium phosphate co-precip-
itation method. Viral titers were measured with the p24 or
p27 RetroTek antigen ELISA kit (ZeptoMetrix, Buffalo,
NY), and viral reverse transcriptase (RT) was quantified
with the Reverse Transcriptase Assay kit (Roche Applied
Science, Mannheim Germany).
Green fluorescence protein (GFP) vector
The HIV-1 vector expressing GFP was prepared as
described previously [36,37]. To construct the HIV-1-WT-
GFP and HIV-1-L4/5S-GFP vector, we replaced the Eco RI-
Apa I fragment corresponding to MA and CA of the
pMDLg/p.RRE packaging vector with those fragments
from NL4-3 and NL-ScaVR, respectively. The GFP viruses
were prepared from 293 T cells in a 15-cm dish by co-
transfection with a combination of 24 g of pMDLg/
p.RRE derivatives, 36 g of CS-CDF-CG-PRE (GFP encod-
ing viral genomic plasmid), 10 g of pMD.G (vesicular
stomatitis virus glycoprotein (VSV-G) expressing plas-
mid), and 10 g of pRSV-Rev (Rev expressing plasmid).
Forty-eight hours after transfection, the culture superna-
tants were collected and used for infection.
Viral infections
3 × 105 MT4 or HSC-F cells were infected with 20 ng of
p24 of NL4-3, NL-ScaV, NL-ScaVR, NL-ScaVR6/7S, NL-
DT5R, or NL-DT5R6/7S. The culture supernatants were
collected periodically, and p24 levels were measured with
an ELISA kit.
Particle purification and Western blotting
The culture supernatant of 293 T cells transfected with
plasmids encoding HIV-1 NL4-3 derivatives was clarified
by means of low speed centrifugation. Nine ml of the
resultant supernatants were layered onto a 2 ml cushion
of 20% sucrose (made in PBS) and centrifuged at 35,000
rpm for 2 h in a Beckman SW41 rotor. After centrifuga-
tion, the virion pellets were resuspended in PBS, and p24
antigen concentrations were measured with ELISA. SDS-
polyacrylamide gel electrophoresis was applied to 120 ng
of p24 of HIV-1 derivatives, and virion-associated pro-
teins were transferred to a PVDF membrane. CA and CypA
proteins were visualized with the anti-p24 antibody
(Biodesign International, Saco, ME) and the anti-CypA
antibody (Affinity BioReagents, Golden, CO), respec-
tively.
Saturation assay
HIV-1 derivatives or SIVmac particles were prepared by
transfecting each of the env-deleted HIV-1 NL4-3 deriva-
tives or SIVmac plasmids with a plasmid encoding VSV-G
into 293 T cells, and culture supernatants were collected
two days after transfection. One day before infection, Rh
LLC-MK2 and hamster TK-ts13 were plated at a density of
5 × 104 cells per well in a 24-well plate. Prior to GFP virus
infection, the cells were pretreated for 2 hours with 200 ng
of p24 of each of the HIV-1 or SIVmac particles pseudo-
typed with VSV-G. Immediately after the pre-treatment,
the cells were washed and infected with the HIV-1-WT-
GFP or HIV-1-L4/5S-GFP virus. Two hours after infection,
the inoculated GFP viruses were washed, and the cells
were cultivated in fresh media. Two days after infection,
the cells were fixed by formaldehyde, and GFP expressing
cells were counted with a flowcytometer. To suppress
endogenous TRIM5 activity, the cells were first infected
with Sendai (SeV) expressing TRIM5 lacking the SPRY
domain at a multiplicity of infection of 10 plaque forming
units per cell. Sixteen hours after SeV infection, the cells
were treated with 200 ng of p24 of the particles and then
infected with the HIV-1-L4/5S-GFP vector as described
above.
Preparation of CD8-depleted CM PBMCs and viral 
infection
CM PBMCs were suspended in RPMI medium 1640 sup-
plemented with 10% (vol/vol) FBS, and the CD8+ cells
were removed with a magnetic bead system (Miltenyi Bio-
tec, Auburn, CA) and stimulated for 1 day with 1 g/ml of
PHA-L (Sigma, St. Louis. MO). For prolonged stimulation,
CD8-depleted CM PBMCs were first stimulated with 1 g/
ml of PHA-L for 2 days and then with human IL2 100 U/
ml for 2 more days. 3 × 105 cells were then inoculated with
200 ng of p24 of NL-DT5R, NL-DT5R6/7S or with 200 ng
of p27 of SIVmac239 and incubated at 37°C in a medium
containing 100 U/ml of human IL2. The culture superna-
tants were collected periodically, and the levels of p24 or
p27 were measured with an antigen capture assay
(Advanced BioScience Laboratories, Kensington, MD)
Results
Construction and characterization of HIV-1 molecular 
clones containing CA and Vif sequences from SIVmac239
Several proviral DNA constructs have been generated to
counteract the restriction of HIV-1 replication in CM T cell
line HSC-F [38] (Fig. 1). We first generated NL-SVR and
NL-ScaVR according to the procedure described by
Kamada et al. [21]. NL-ScaVR, a virus with SIVmac239 L4/
5 CA and vif, could replicate slowly in HSC-F and repli-
cated well in MT4 as previously reported (Fig. 2A). We
recently discovered that the 120th amino acid of CA
affected the sensitivity of HIV-2 to CM TRIM5 [32]. We,
therefore, introduced an additional amino acid substitu-
tion, His to Gln, at this position in NL-ScaVR. The result-
ant virus was designated NL-ScaVRA1; but this virus
unexpectedly showed less efficient replication than did
the parental NL-ScaVR in both MT4 and HSC-F cells (Fig.
2A), probably due to a reduced viral fitness created by this
mutation. We, therefore, replaced the entire L6/7 CA of
NL-ScaVR (HNPPIP) with the corresponding loop from
SIVmac239 (RQQNPIP), and the resultant virus was des-Retrovirology 2009, 6:70 http://www.retrovirology.com/content/6/1/70
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ignated NL-ScaVR6/7S. The amount of RT per 1 ng of CA
of NL-ScaVR (0.083 ng) was comparable to that of NL-
ScaVR6/7S (0.081 ng), indicating that the replacement of
L6/7 in HIV-1 with the corresponding loop of SIVmac did
not affect the reactivity of CA antigen. Although NL-
ScaVR6/7S grew slightly slower in MT4 cells, it could rep-
licate more efficiently in HSC-F cells than the parental NL-
ScaVR could (Fig. 2A). Similar results were obtained when
we inoculated 20 ng of RT equivalent of NL-ScaVR or NL-
ScaVR6/7S into HSC-F cells and measured the periodic RT
production in culture supernatants (data not shown).
These findings demonstrated that L6/7 CA of SIVmac
improved the replication in CM cells of an HIV-1 deriva-
tive that already contained a SIVmac L4/5 and vif. We then
generated NL-SVR6/7S, in which the L4/5 sequence was
from HIV-1, but the L6/7 and vif came from SIVmac. NL-
SVR6/7S showed better replication than NL-ScaVR6/7S in
MT4 cells, but lost its replicative capability in HSC-F cells
(Fig. 2B). NL-SVR, a virus with SIVmac vif, could replicate
in MT4, but failed to do so in HSC-F (Fig. 2B). These
results indicated that both L4/5 and L6/7 of SIVmac are
required for efficient replication in HSC-F.
Structure of the chimeric HIV-1/SIVmac clones and a summary of their replication capabilities Figure 1
Structure of the chimeric HIV-1/SIVmac clones and a summary of their replication capabilities. White bars 
denote HIV-1 (NL4-3) and gray bars SIVmac239 sequences. ++++, +++, ++, +, and -denote the peak titer of virus growth in 
human (Hu) and cynomolgus monkey (CM) cells, respectively, to more than 1000 ng/ml, 100–1000 ng/ml, 10–100 ng/ml, 1–10 
ng/ml, and less than 1 ng/ml concentration of capsid (CA) protein in the culture supernatants. * denotes that NL-DT5R6/7S 
replicated faster in HSC-F than did the parental NL-DT5R (see Fig. 2C).
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Replication properties of HIV-1 derivatives Figure 2
Replication properties of HIV-1 derivatives. Equal amounts of (A) NL-ScaVR (white diamonds: virus with SIVmac L4/5 
and vif), and NL-ScaVRA1 (gray diamonds: virus with additional replacement of the 120th amino acid His with Gln in NL-
ScaVR), and NL-ScaVR6/7S (black diamonds: virus with SIVmac L4/5, L6/7, and vif) (B) NL-SVR, NL-ScaVR6/7S, and NL-SVRS6/
7S (gray diamonds: virus with SIVmac L6/7 and vif), and (C) NL-DT5R (white squares) and NL-DT5R6/7S (black squares), were 
inoculated into human MT4 or CM HSC-F cells, and culture supernatants were collected periodically. p24 antigen levels were 
measured by ELISA.
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We then introduced SIVmac L6/7 into NL-DT5R, a molec-
ularly cloned virus with two nonsynonymous changes in
the  env  gene gained during long-term passages of NL-
ScaVR in HSC-F cells [21]. The resultant virus was desig-
nated NL-DT5R6/7S. Although the peak titer of NL-
DT5R6/7S was almost the same as that of NL-DT5R, NL-
DT5R6/7S could replicate faster in HSC-F than the paren-
tal NL-DT5R (Fig. 2C). This finding confirmed that SIV-
mac L6/7 CA sequence improved the replication in CM
cells of HIV-1 derivatives that contained SIVmac L4/5 and
vif. The finding suggested that HIV-1 L6/7 and L4/5 CA
sequences are important for intrinsic restriction in CM
cells.
CypA incorporation into virus particles was not affected by 
replacement of HIV-1 L6/7 with that of SIVmac
Several studies have demonstrated that CypA augments
HIV-1 infection in human cells [39], but inhibits its repli-
cation in OWM cells [18-20]. CypA was packaged in HIV-
1 but not in SIVmac virus particles. To determine whether
the replacement of HIV-1 L6/7 with that of SIVmac affects
CypA binding of HIV-1 CA, we performed Western blot
analysis of viral particles from HIV-1 derivatives. As
shown in Fig. 3 (upper panel), CypA proteins were clearly
detected in the NL-SVR particles (lane 1) but not in those
of NL-ScaVR (lane 3), thus confirming that the L4/5
sequence of HIV-1 but not of SIVmac is required for CypA
incorporation into viral particles. CypA proteins were
detected in NL-SVR6/7S (lane 2) but not in NL-ScaVR6/7S
(lane 4), indicating that the additional replacement of
HIV-1 L6/7 with that of SIVmac had little effect on CypA
incorporation. This finding suggests that the effect of L6/
7 replacement on viral growth was independent from
CypA binding of HIV-1 CA. When we used anti-p24 anti-
body (Fig. 3, lower panel), p55 Gag precursors and p24
proteins were clearly detected. There were no differences
in the amount of p24 or the ratio of p24 to p55 among the
four HIV-1 derivatives, indicating that the HIV-1 Gag pre-
cursor proteins with SIVmac L4/5 and L6/7 were proc-
essed normally by the viral protease.
Replacement of both L4/5 and L6/7 of HIV-1 CA with the 
corresponding loops from SIVmac impaired the CA binding 
activity of TRIM5 in Rh cells
It is known that the intrinsic restriction factors working
against HIV-1 in CM and Rh cells can be saturated by inoc-
ulation of a high dose of HIV-1 particles [19,40-42]. To
determine whether alteration in the CA of HIV-1 would
affect its ability to saturate restriction factors, Rh LLC-MK2
cells were pre-treated with equal amounts of VSV-G pseu-
dotyped HIV-1 particles that were with or without SIVmac
L4/5 and/or L6/7 CA to saturate intrinsic restriction fac-
tor(s). The pre-treated cells were then infected with GFP-
expressing HIV-1 carrying SIVmac L4/5 CA (HIV-1-L4/5S-
GFP), since we wanted to exclude any effects of CypA on
the GFP expressing virus in LLC-MK2 cells. The suscepti-
bility of particle-treated cells to virus infection was deter-
mined by the percentage of GFP-positive cells. The cells
treated with the wild type (WT) particles showed greatly
enhanced susceptibility to HIV-1 infection compared with
non-treated cells (Fig. 4A, left), demonstrating that the
intrinsic restriction factor(s) in LLC-MK2 cells were satu-
rated by a high dose of particles. The cells treated with the
particles carrying SIVmac L4/5 and those treated with par-
ticles carrying SIVmac L6/7 also showed enhanced suscep-
tibility to HIV-1 infection (Fig. 4A, left). The cells treated
with particles carrying both SIVmac L4/5 and L6/7
showed only slight enhancement of HIV-1 susceptibility
(Fig. 4A, left; p = 0.007 compared by means of paired t test
using all data points with the WT particle treated cells).
Similarly, the cells treated with SIVmac particles showed
only minor enhancement in HIV-1 susceptibility (Fig. 4A,
left). Hamster TK-ts13 cells which lack TRIM5 expres-
Western blot analysis of CA and CypA in particles of HIV-1  derivatives Figure 3
Western blot analysis of CA and CypA in particles of 
HIV-1 derivatives. The viral particles of NL-SVR (lane 1), 
NL-SVR6/7S (lane 2), NL-ScaVR (lane 3) and NL-ScaVR6/7S 
(lane 4) were purified by ultracentrifugation through a 20% 
sucrose cushion. CypA (upper panel) and p24 and p55 pro-
teins (lower panel) were visualized by Western blotting 
(WB) using anti-CypA and anti-p24 antibody, respectively. 
"H" and "S" denote the amino acid sequences derived from 
HIV-1 and SIVmac, respectively.
WB: α-CypA
L4/5 HS S H
L6/7 SS H H
WB: α-p24
Vif SSSS
62
49
38
28
(kDa)
CypA
p55
p24
NL-SVR
2: NL-SVR6/7S
3: NL-ScaVR
4: NL-ScaVR6/7SRetrovirology 2009, 6:70 http://www.retrovirology.com/content/6/1/70
Page 7 of 11
(page number not for citation purposes)
Saturation of intrinsic antiviral factors resulting from inoculation of high dose of virus particles Figure 4
Saturation of intrinsic antiviral factors resulting from inoculation of high dose of virus particles. (A) Rhesus LLC-
MK2 cells or hamster TK-ts13 cells were pre-treated with equal amounts of VSV-G pseudotyped particles with WT HIV-1 
(white squares: Wt), with SIVmac L4/5 (white triangles: 4/5S), with SIVmac L6/7 (white circles: 6/7S), with SIVmac L4/5 and L6/
7 (white diamonds: 4/5S6/7S), with SIVmac239 (pluses: SIVmac) or none (crosses) for 2 hours. The cells were then infected 
with the GFP expressing HIV-1 vector carrying SIVmac L4/5 (A: HIV-1-L4/5S-GFP) or GFP expressing HIV-1 vector with WT 
capsid (B: HIV-1-WT-GFP). Representative data of four independent experiments are shown. (C) Saturation activities were 
assessed in the presence or absence of functional TRIM5. Before particle treatment, cells were infected with Sendai virus 
(SeV) expressing TRIM5 without the SPRY domain (black symbols), or an empty vector, parental Z strain of SeV (white sym-
bols). Sixteen hours after SeV infection, cells were treated with particles for 2 hours and then infected with HIV-1-L4/5S-GFP. 
Representative data from six independent experiments are shown.
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sion, on the other hand, showed no difference in HIV-1
susceptibility among cells treated with various HIV-1
derivatives or SIVmac particles (Fig. 4A, right). As shown
in Fig. 4B, similar results were obtained when we used a
GFP-expressing virus with WT HIV-1 capsid (HIV-1-WT-
GFP). These results indicate that both HIV-1 L4/5 and L6/
7 are important for CA binding to antiviral factor(s) in Rh
cells. As described previously [20], HIV-1-WT-GFP could
induce infection in only small numbers of LLC-MK2 cells.
In contrast, more TK-ts13 cells were infected with HIV-1-
WT-GFP than with HIV-1-L4/5-GFP. It is thus possible
that CypA is a supporting factor for HIV-1 replication in
hamster cells as well as in human cells.
Endogenous TRIM5 seems to be a likely candidate for
the antiviral factor saturated by a high dose of HIV-1 par-
ticles (Fig. 4A and 4B). To confirm this, we assessed the
ability of WT and mutant HIV-1 particles to saturate the
intrinsic restriction factor in the presence or absence of
functional TRIM5. The dominant negative effect of an
over-expressed TRIM5 mutant lacking SPRY domain [43]
was used to suppress the function of cell endogenous
TRIM5. As shown in Fig. 4C, the infection of a recom-
binant SeV expressing TRIM5 without the SPRY domain
caused marked enhancement of HIV-1-L4/5S-GFP virus
infection without prior particle treatment (crosses vs.
asterisks). This indicates that this dominant negative
TRIM5 mutant successfully suppressed the restriction
activity of endogenous TRIM5. Treatment with the WT
HIV-1 particles also saturated the restriction factors in the
cells infected with the empty vector virus (parental Z
strain of SeV), while the additional effect of the dominant
negative mutant TRIM5 remained unclear (Fig. 4C left,
white vs. black squares). These results suggest that the
intrinsic factors saturated by the WT particles were mainly
endogenous TRIM5. In contrast to the effect of the WT
particle treatment, the effect of the dominant negative
TRIM5 mutant on HIV-1 infection was evident when we
used particles with SIVmac L4/5 and L6/7 (Fig. 4C, right,
white vs. black diamonds, p = 0.007, paired t test). These
findings suggest that the diminished capability of particles
with SIVmac L4/5 and L6/7 to saturate restriction factors
was mainly due to their loss of interaction with TRIM5.
We, therefore, concluded that the ability of HIV-1 with
SIVmac L4/5 and L6/7 to bind to TRIM5 is diminished
in LLC-MK2 cells.
HIV-1 derivative with SIVmac L4/5, L6/7, and vif sequences 
can replicate efficiently in monkey primary cells
To verify the effect of additional replacement of HIV-1 L6/
7 with that of SIVmac in primary CM cells, we prepared
PBMCs from CM and removed CD8+ cells by means of
magnetic beads. The cells were then stimulated for 1 day
with 1 g/ml of PHA-L. NL-DT5R6/7S showed more effi-
cient replication than did the parental NL-DT5R in these
cells and reached its peak titer 8 days after infection (Fig.
5A). For prolonged stimulation, CD8-depleted CM
PBMCs were first stimulated with 1 g/ml of PHA-L for 2
days and then with human IL2 100 U/ml for 2 more days.
In these cells, NL-DT5R with HIV-1 L6/7 did not grow at
all. On the other hand, NL-DT5R with SIVmac L6/7 (NL-
DT5R6/7S) grew in CM primary cells in response to pro-
longed stimulation by PHA and IL-2 to reach titers, simi-
lar to those attained in cells with short stimulation, up to
8 days after infection (Fig. 5A and 5B). Furthermore, NL-
DT5R6/7S continued to grow to much higher titers and
reached its peak titer 16 days after infection; this higher
peak may be due to better proliferation of these cells than
those cells receiving short term stimulation (Fig. 5B).
These results confirmed that the replicative capability of
HIV-1 in CM cells was augmented by the additional
replacement of L6/7 of CA with the corresponding
sequence from SIVmac.
Discussion
We created simian-tropic HIV-1 with more efficient repli-
cation capability in CM cells using the knowledge
obtained from our previous study of TRIM5 and HIV-2
capsid sequence variations [32] Introduction of the entire
SIVmac L6/7 CA into the previously constructed version
of HIV-1 derivatives containing SIVmac L4/5 CA and vif
[21] caused only a four amino acid change in CA but
Replication capabilities of HIV-1 derivatives in peripheral  blood mononuclear cells (PBMC) from CM Figure 5
Replication capabilities of HIV-1 derivatives in 
peripheral blood mononuclear cells (PBMC) from 
CM. (A) PBMCs were obtained from CM, after which the 
CD8+ cells were removed, and the cells were stimulated 
with PHA-L for 1 day. (B) CD8-depleted CM PBMC were 
first stimulated with 1 g/ml of PHA-L for 2 days and then 
with human IL2 100 U/ml for 2 more days. Equal amounts of 
p24 of NL-DT5R (white squares) or NL-DT5R6/7S (black 
squares) were inoculated, and the culture supernatants were 
collected periodically. p24 antigen levels were measured by 
ELISA. Values represent means with actual fluctuations of 
duplicate samples added. The values for mock infected cell 
culture supernatants were zero in the ELISA assay.
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showed improved replication capability of HIV-1 in the
CM cell line HSC-F. Introduction of the entire SIVmac L6/
7 CA into NL-DT5R, which has two additional amino acid
mutations in the env gene, enhanced replication in CD8+
cells-depleted CM PBMCs. After prolonged stimulation of
CM PBMCs, replication of the original version of NL-
DT5R was suppressed while that of NL-DT5R with SIVmac
L6/7 was not. It would thus be of interest to test whether
those HIV-1 derivatives with both L4/5 andL6/7 from SIV-
mac can induce infection of CM in vivo.
While the high-dose inoculation of WT HIV-1 particles
into Rh cells saturated endogenous TRIM5 and
enhanced subsequent infection with HIV-1, the introduc-
tion of HIV-1 particles that contained both L4/5 and L6/7
from SIVmac greatly impaired the ability of the particles
to saturate TRIM5. When we replaced either HIV-1 L4/5
or L6/7 with the corresponding sequence from SIVmac,
these particles still saturated TRIM5. These findings sug-
gest that TRIM5 recognized the overall structure com-
posed of both L4/5 and L6/7 of HIV-1 CA. Our previous
results from computational 3D-structure modeling analy-
sis of HIV-2 CA support this hypothesis [32]. The 120th
amino acid of HIV-2 CA, which affects viral susceptibility
to TRIM5 restriction, was located in L6/7. It is especially
worth noting that the amino acid substitution at the
120th position was previously predicted to induce
marked changes in the configuration of L6/7 and the L6/
7 with the CM TRIM5-sensitive Pro positioned most
closely to L4/5 of HIV-2 [32]. It would, therefore, be inter-
esting to investigate whether monkey TRIM5 proteins
recognize CypA bound-L4/5 of HIV-1 CA.
During the preparation of our manuscript, Lin and Emer-
man reported that SIVagmTAN with both HIV-1 L4/5 and
L6/7 was susceptible to Rh-TRIM5 restriction [44]. Our
result is consistent with their finding, since the HIV-1 par-
ticles with both SIVmac L6/7 and SIVmac L4/5 showed
reduced saturation activity for TRIM5 in Rh cells com-
pared with HIV-1 particles with SIVmac L4/5 alone. Hatz-
iioannou et al. very recently reported that stHIV-1 strains,
which differ from HIV-1 only in the vif gene, could effi-
ciently replicate in pig-tailed monkey and proposed a pig-
tail monkey model of HIV-1 infection [45]. This is not sur-
prising, since pig-tailed monkeys lack a TRIM5 protein,
and the dominant form of TRIM5 expressed in this mon-
key species is a TRIMCyp fusion protein lacking anti-HIV-
1 activity [46-48].
When we subjected CD8-depleted CM PBMC to pro-
longed stimulation, NL-DT5R6/7S grew efficiently but
NL-DT5R did not. Since the expression levels of TRIM5
mRNA in human PBMC increased after stimulation with
PHA and IL2 for 3 days (data not shown), we speculated
that the higher expression levels of CM-TRIM5 in fully
stimulated CM cells resulted in efficient restriction of NL-
DT5R. However, no clear enhancement of CM TRIM5
mRNA expression could be detected in the CM cells sub-
jected to prolonged stimulation (data not shown). The
reason why NL-DT5R failed to grow in CM cells with pro-
longed stimulation is not yet clear, but it is possible that
fully stimulated CM cells exerted stronger intrinsic inhib-
itory activity against HIV-1 infection than those with
short-term stimulation.
NL-DT5R6/7S and NL-ScaVR6/7S replicated less effi-
ciently in human MT4 cells than did the parental NL-
DT5R and NL-ScaVR. One possible explanation is that the
virus with SIVmac L6/7 became resistant to CM TRIM5
but became more sensitive to human TRIM5, since the
latter can restrict SIVmac more efficiently than HIV-1.
Another possibility is that replacement of CA allowed the
virus to evade the intrinsic inhibitory factors in CM cells
but impaired viral replication per se.
We used the CM T cell line HSC-F and CD8+ cell-depleted
PBMC from CM but not from Rh for our replication exper-
iments. Although we observed an improvement of viral
replication in CM cells, we cannot assume that the
replacement of L4/5 and L6/7 is enough for HIV-1 to rep-
licate to high titers in Rh cells since the CM TRIM5 resist-
ant HIV-2 mutant virus GH123 (Q) was found to be
restricted by Rh TRIM5 [34]. NL-DT5R6/7S and NL-
ScaVR6/7S also showed less efficient replication capabil-
ity than did SIVmac (Fig. 1). We are currently trying to
adapt these viruses to CM and Rh cells by means of long-
term passaging in the hope of introducing compensating
mutations that can overcome these disadvantages and fur-
ther augment their replicative capabilities in human and
simian cells to reach a similar level as seen with SIVmac.
Conclusion
We have succeeded in improving simian-tropic HIV-1 for
more efficient replication in CM cells by introduction of
the SIVmac L6/7 CA sequence. It will be of interest to
determine whether the HIV-1 derivatives with SIVmac L4/
5 and L6/7 can induce infection in cynomolgus monkeys
in vivo. Even if they fail to do so, further modification and/
or adaptation of the current version of simian-tropic HIV-
1 in monkey cells might be expected to lead to the devel-
opment of an HIV-1 infection model in OWMs. This
model has been long-awaited as a tool for vaccine devel-
opment and as a model for better understanding of AIDS
pathogenesis.
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